Pro-Resolution Mediator Lipoxin A4 and its Receptor in Upper Airway Inflammation

Abstract

Objectives:

The resolution of inflammation is an active process controlled by several anti-inflammatory and pro-resolution mediators. Lipoxin A4, an endogenous lipid mediator, is a potential pro-resolution mediator that could attenuate inflammation. This study was conducted to elucidate the role of lipoxin A4 in upper airway inflammation.

Methods:

Nasal secretions were collected from patients with chronic rhinosinusitis with nasal polyposis, patients with allergic rhinitis, and control subjects. The concentration of lipoxin A4 was measured by enzyme-linked immunosorbent assay. Nasal tissues were obtained from nasal polyps and inferior turbinates during endonasal surgery. The mRNA expressions of lipoxygenases (LOXs), lipoxin receptor (formyl peptide receptor-like 1; FPRL-1), and cysteinyl leukotriene type 1 receptor (CysLT1R) in nasal tissues were examined by reverse-transcription polymerase chain reaction. Tissue localization of FPRL-1 was determined by immunohistochemical staining. The in vitro effect of lipoxin A4 on airway epithelial cells was also examined.

Results:

A significant concentration of lipoxin A4 was found in nasal secretions, and the concentration was increased in patients with allergic rhinitis. The mRNA expressions of 5-LOX, 15-LOX-1, FPRL-1, and CysLT1R were significantly greater in nasal polyps than in inferior turbinates. FPRL-1 was localized in nasal epithelial cells. Lipoxin A4 inhibited tumor necrosis factor α-induced interleukin 8 release from airway epithelial cells via its receptor FPRL-1.

Conclusions:

These results indicate that lipoxin A4 may play a role in the resolution of upper airway inflammation. A low concentration of lipoxin A4 may be involved in chronic inflammation of the upper airways.

Keywords

allergic rhinitis chronic rhinosinusitis formyl peptide receptor-like 1 lipoxin A4 lipoxygenase nasal polyp

Get full access to this article

View all access options for this article.

References

Haworth

Levy

. Endogenous lipid mediators in the resolution of airway inflammation. Eur Respir J 2007;30:980–92.

Maderna

Godson

. Lipoxins: Resolutionary road. Br J Pharmacol 2009;158:947–59.

Karp

Flick

Park

. Defective lipoxinmediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004;5:388–92.

Levy

Bonnans

Silverman

Palmer

Marigowda

Israel

; Severe Asthma Research Program, National Heart, Lung, and Blood Institute. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005;172:824–30.

Planagumà

Kazani

Marigowda

. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574–82.

Levy

Lukacs

Berlin

. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007;21:3877–84.

Thomas

Yawn

Price

Lund

Mullol

Fokkens

; European Position Paper on Rhinosinusitis and Nasal Polyps Group. EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 — A summary. Prim Care Respir J 2008;17:79–89.

Global Initiative for Asthma (GINA), National Heart, Lung, and Blood Institute, eds. Global strategy for asthma management and prevention. Bethesda, Md: NHLBI, 2006.

Committee of the Practical Guideline for the Management of Allergic Rhinitis, eds. Practical guideline for the management of allergic rhinitis in Japan. Tokyo, Japan: Life Science Publishing, 2009.

10.

Pérez-Novo

Watelet

Claeys

Van Cauwenberge

Bachert

. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005;115:1189–96.

11.

Rostkowska-Nadolska

Kapral

Fraczek

Kowalczyk

Gawron

Mazurek

. A microarray study of gene expression profiles in nasal polyps. Auris Nasus Larynx 2011;38:58–64.

12.

Claesson

. On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma. Prostaglandins Other Lipid Mediat 2009;89:120–5.

13.

Serhan

Jain

Marleau

. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003;171:6856–65.

14.

Hsi

Wilson

Eling

. Opposing effects of 15-lipoxygenase-1 and −2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator–activated receptor gamma. J Biol Chem 2002;277:40549–56.

15.

Mangino

Brounts

Harms

Heise

. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 2006;79:84–92.

16.

Bonnans

Gras

Chavis

. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed Pharmacother 2007;61:261–7.

17.

Romano

Recchia

Recchiuti

. Lipoxin receptors. Scientific World Journal 2007;7:1393–412.

18.

József

Zouki

Petasis

Serhan

Filep

. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-χB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 2002;99:13266–71.

19.

Kure

Nishiumi

Nishitani

. Lipoxin A4 reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor–χB activation. J Pharmacol Exp Ther 2010;332:541–8.

20.

S-H

Liao

P-Y

Dong

Chen

Z-Q

. Signal pathway involved in inhibition by lipoxin A4 of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm Res 2008;57:430–7.